Literature DB >> 35070430

Prognostic prediction and gene regulation network of EIF2S2 in hepatocellular carcinoma based on data mining.

Piyou Ji1, Haitao Wang1, Yu Cheng1, Shaohua Liang2.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a malignant tumor with a high fatality rate, predicting poor prognosis and therapeutic effect. Screening potential prognostic genes in HCC could be a creative way to advance clinical treatment. Eukaryotic translation initiation factor 2 subunit beta (EIF2S2) has reportedly been linked to several tumors, including liver cancer, but the prognostic predictions remain unknown. Therefore, we aimed to clarify the prognostic role and interaction network of EIF2S2 in HCC using bioinformatics data.
METHODS: We screened EIF2S2 using the Oncomine, Ualcan, and TCGA databases. R software was used to analyze the mRNA level and clinicopathological characteristics of hepatocellular carcinoma. Evaluation of the correlations between EIF2S2 and patients' survival was made using the Kaplan-Meier curves and Cox proportional hazards regression model. Then, the influence of EIF2S2 gene mutations on the prognosis of patients was explored by cBioPortal. The protein-protein interaction network of 50 similar genes related to EIF2S2 was implemented by GEPIA2 and Metascape. The LinkedOmics database allowed us to carry out Gene Set Enrichment Analysis. Finally, we constructed the EIF2S2 kinase, miRNA, and transcription factor target networks using GeneMANIA.
RESULTS: EIF2S2 mRNA was overexpressed in HCC and was closely associated with clinicopathological features, including gender, age, race, tumor grade, and stage. There was no correlation between EIF2S2 genetic mutations and prognostic survival. Combining Cox proportional hazards regression model analyses, high-expressed EIF2S2 predicted poor prognosis in HCC patients. Additionally, we screened the top three EIF2S2-related genes (PFDN4, HM13, and SNRPD1), the 50 similar genes, and then constructed a 50-similar-gene protein-protein interaction network identified by the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using Metascape. EIF2S2 target networks in HCC were identified in kinase, miRNA, and transcription factor networks, including the mitogen-activated protein kinase 1 (MAPK1), miRNAs (Mir-144), and transcription factors (GGAANCGGAANY_UNKNOWN) using GeneMANIA.
CONCLUSIONS: EIF2S2 plays a crucial role in the gene-regulating network of HCC and may be a potential prognostic marker or therapeutic target for HCC patients. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); bioinformatics; eukaryotic translation initiation factor 2 subunit beta (EIF2S2); prediction; prognosis

Year:  2021        PMID: 35070430      PMCID: PMC8748036          DOI: 10.21037/jgo-21-748

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  79 in total

1.  Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients.

Authors:  Balázs Gyorffy; András Lánczky; Zoltán Szállási
Journal:  Endocr Relat Cancer       Date:  2012-04-10       Impact factor: 5.678

2.  Multiple genes identified as targets for 20q13.12-13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma.

Authors:  Dong Wang; Zhong-Zheng Zhu; Hongmei Jiang; Jiayi Zhu; Wen-Ming Cong; Bing-Ji Wen; Song-Qin He; Shu-Fang Liu
Journal:  Hepatol Int       Date:  2015-06-12       Impact factor: 6.047

Review 3.  Proteasome dysregulation in human cancer: implications for clinical therapies.

Authors:  Yulin Chen; Yanan Zhang; Xing Guo
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

4.  Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma.

Authors:  Hien Dang; Atsushi Takai; Marshonna Forgues; Yotsowat Pomyen; Haiwei Mou; Wen Xue; Debashish Ray; Kevin C H Ha; Quaid D Morris; Timothy R Hughes; Xin Wei Wang
Journal:  Cancer Cell       Date:  2017-07-10       Impact factor: 31.743

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

6.  Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy.

Authors:  Virginie Quidville; Samar Alsafadi; Aïcha Goubar; Frédéric Commo; Véronique Scott; Catherine Pioche-Durieu; Isabelle Girault; Sonia Baconnais; Eric Le Cam; Vladimir Lazar; Suzette Delaloge; Mahasti Saghatchian; Patricia Pautier; Philippe Morice; Philippe Dessen; Stéphan Vagner; Fabrice André
Journal:  Cancer Res       Date:  2013-01-28       Impact factor: 12.701

7.  miR-144 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting E2F3.

Authors:  Tingjia Cao; Hanjun Li; Yilin Hu; Dandan Ma; Xun Cai
Journal:  Tumour Biol       Date:  2014-07-30

8.  The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B.

Authors:  Qinhao Guo; Yong Wu; Xueqi Guo; Lijie Cao; Fei Xu; Haiyun Zhao; Jun Zhu; Hao Wen; Xingzhu Ju; Xiaohua Wu
Journal:  Mol Ther Nucleic Acids       Date:  2020-10-15       Impact factor: 8.886

9.  The RNA-binding protein SERBP1 functions as a novel oncogenic factor in glioblastoma by bridging cancer metabolism and epigenetic regulation.

Authors:  Adam Kosti; Patricia Rosa de Araujo; Wei-Qing Li; Gabriela D A Guardia; Jennifer Chiou; Caihong Yi; Debashish Ray; Fabiana Meliso; Yi-Ming Li; Talia Delambre; Mei Qiao; Suzanne S Burns; Franziska K Lorbeer; Fanny Georgi; Markus Flosbach; Sarah Klinnert; Anne Jenseit; Xiufen Lei; Carolina Romero Sandoval; Kevin Ha; Hong Zheng; Renu Pandey; Aleksandra Gruslova; Yogesh K Gupta; Andrew Brenner; Erzsebet Kokovay; Timothy R Hughes; Quaid D Morris; Pedro A F Galante; Stefano Tiziani; Luiz O F Penalva
Journal:  Genome Biol       Date:  2020-08-06       Impact factor: 13.583

10.  RNA-binding protein Musashi2 stabilizing androgen receptor drives prostate cancer progression.

Authors:  Jing Zhao; Yu Zhang; Xi-Sheng Liu; Fang-Ming Zhu; Feng Xie; Chen-Yi Jiang; Zi-Ye Zhang; Ying-Li Gao; Yong-Chuan Wang; Bin Li; Shu-Jie Xia; Bang-Min Han
Journal:  Cancer Sci       Date:  2020-01-04       Impact factor: 6.716

View more
  2 in total

1.  Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma.

Authors:  Genhao Zhang; Xianping Lv; Qiankun Yang; Hongchun Liu
Journal:  BMC Cancer       Date:  2022-08-13       Impact factor: 4.638

2.  Long noncoding RNA LINC01132 enhances immunosuppression and therapy resistance via NRF1/DPP4 axis in hepatocellular carcinoma.

Authors:  Jiwei Zhang; Tao Pan; Weiwei Zhou; Ya Zhang; Gang Xu; Qi Xu; Si Li; Yueying Gao; Zhengtao Wang; Juan Xu; Yongsheng Li
Journal:  J Exp Clin Cancer Res       Date:  2022-09-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.